Understanding Diabetic Ketoacidosis
Diabetic ketoacidosis (DKA) is an acute metabolic crisis marked by three convergent pathologies: hyperglycemia (blood glucose >250 mg/dL), metabolic acidosis (arterial pH <7.3 with bicarbonate <15 mEq/L), and ketonemia or ketonuria. It occurs predominantly in type 1 diabetes when pancreatic beta cells produce insufficient or no insulin, but relative insulin deficiency during sepsis, myocardial infarction, or surgery can precipitate it in type 2 diabetics. Often DKA is the initial presentation of undiagnosed type 1 diabetes.
The pathophysiology hinges on insulin lack. Without insulin, glucose cannot cross cell membranes despite soaring blood levels—tissues starve while hyperglycemia worsens. Simultaneously, the body mobilises fatty acids for energy, overwhelming hepatic ketone synthesis. Beta-hydroxybutyrate and acetoacetate accumulate, dissociate into protons and ketoanions, and drive profound acidosis.
DKA Diagnostic and Mortality Criteria
The ADA defines DKA using four core laboratory findings. Severity escalates from mild to moderate to severe based on pH and bicarbonate thresholds. Additionally, in-hospital mortality risk incorporates comorbidity burden, pH recovery, insulin demand, glycemic control at 12 hours, fever, and altered mental status.
DKA Diagnosis (all four required):
• Glucose >250 mg/dL (>13.8 mmol/L)
• Arterial pH <7.3
• Bicarbonate <15 mEq/L
• Serum or urine ketones present
Mortality Risk = f(comorbidities, pH at 24h, insulin req., glucose at 12h, mental status, temperature)
Glucose— Serum glucose level in mg/dL; DKA threshold >250 mg/dLpH— Arterial blood pH; <7.3 indicates acidosis; severity worsens as pH fallsBicarbonate— Serum bicarbonate concentration in mEq/L; <15 mEq/L is diagnostic; lower values reflect greater acid burdenSerum ketones— Beta-hydroxybutyrate or acetoacetate measured in blood; presence confirms ketosisAnion gap— Calculated as Na⁺ − (Cl⁻ + HCO₃⁻); elevated gap indicates accumulation of unmeasured anions (ketones)Comorbidities— Immunosuppression, COPD, prior MI/stroke, cirrhosis, or heart failure; each increases mortality riskMental status— Ranges from alert to stupor to coma; reflects cerebral edema severity
Pathophysiology: From Insulin Lack to Acidosis
When insulin is absent or ineffective, hepatic ketogenesis accelerates unchecked. Free fatty acid flux to the liver triples or quadruples; each molecule is oxidised to acetyl-CoA, which is diverted from the citric acid cycle into ketone body synthesis. The two predominant ketones—beta-hydroxybutyrate (~70%) and acetoacetate (~30%)—are strong organic acids.
In blood, these ketones dissociate: H⁺ + ketoanion. The hydrogen ions bind available bicarbonate:
H⁺ + HCO₃⁻ → H₂CO₃ → H₂O + CO₂
This consumes the body's principal buffer, hence bicarbonate plummets. Respiratory compensation—rapid, deep Kussmaul breathing—attempts to exhale CO₂ and restore pH, but cannot overcome the ketone load. Meanwhile, the low extracellular pH drives a transmembrane potassium shift: H⁺ ions enter cells to dilute intracellular acid, displacing K⁺ outward. Serum potassium rises paradoxically—hyperkalemia—despite total body depletion. This creates a dangerous arrhythmia risk even as the patient is potassium-depleted overall.
Clinical Presentation and Red Flags
Symptoms develop rapidly over hours. Patients report polyuria (excessive thirst-driven urination), polydipsia (extreme thirst), fatigue, and nausea or vomiting. Abdominal and chest discomfort may occur. On examination, the clinician observes tachycardia, hypotension, dehydration signs (poor skin turgor, dry mucous membranes), and characteristic Kussmaul respiration—a rapid, deep, laboured pattern audible at the bedside.
Altered mental status—from lethargy to obtundation to coma—signals cerebral oedema, a medical emergency. The mechanism involves osmotic shifts: high glucose and ketones raise extracellular osmolality; water moves into cells, causing swelling and raised intracranial pressure. Coma or seizures carry mortality rates exceeding 10%. Other poor prognostic signs include sepsis (present in ~20% of cases), acute kidney injury, and high anion gap (>12 mEq/L).
Clinical Assessment Pitfalls
Clinicians must avoid diagnostic and management missteps in acute DKA.
- Euglycemic DKA with SGLT2 inhibitors — Newer diabetes agents (canagliflozin, dapagliflozin) increase urinary glucose loss, sometimes maintaining near-normal serum glucose despite profound ketoacidosis. Blood glucose <250 mg/dL does <em>not</em> exclude DKA. If a patient on SGLT2 inhibitors presents with Kussmaul breathing, nausea, and abdominal pain, check pH and ketones first.
- Bicarbonate paradox and serum potassium management — Profound hypokalaemia lurks beneath normal or high serum K⁺ levels. As acidosis corrects with insulin and fluids, potassium shifts intracellularly, causing dangerous hypokalaemia. Continuous cardiac monitoring and frequent potassium recheck (every 2–4 hours initially) are mandatory. Replace potassium early and generously.
- Anion gap closure and hyperchloremic acidosis — Early in DKA treatment, ketones clear faster than sodium or chloride normalise, occasionally creating a non-anion-gap (hyperchloremic) acidosis. This is self-limited but reflects ongoing renal losses and poor hydration status. Persistent hyperchloremic acidosis after 24 hours warrants review of fluid composition and consideration of underlying renal or gastrointestinal losses.
- Non-diabetic and alcoholic ketoacidosis — DKA occurs almost exclusively in type 1 diabetes, but starvation and alcohol abuse can provoke ketoacidosis in non-diabetics. Likewise, patients with type 2 diabetes and severe infections may develop DKA if insulin demand overwhelms supply. Always measure C-peptide if diabetes history is unclear, and ask about alcohol and dietary intake.